anti-SARS-CoV-2 convalescent plasma / Mayo Clinic - LARVOL DELTA

The Safety Profile of COVID-19 Convalescent Plasma. (PubMed, Curr Top Microbiol Immunol) - "The well-known complications of blood and plasma transfusions-transfusion-associated circulatory overload and transfusion-related acute lung injury-were found with no higher incidence than with standard use of blood and plasma, nor was there evidence for antibody-dependent enhancement or increased incidence of thromboembolic events. The comprehensive safety profile derived from studies enrolling hundreds of thousands of recipients of COVID-19 convalescent plasma across the world should allay safety fears about the rapid deployment of convalescent plasma in future pandemics."

Journal • Acute Lung Injury • Cardiovascular • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Respiratory Diseases

Using Passive Antibody Therapies in the Next Pandemic. (PubMed, Curr Top Microbiol Immunol) - "However, convalescent plasma therapy can be available as soon as there are survivors and is likely to be effective if used early and in sufficient strength...We cannot afford to wait until the next pandemic is upon us to respond. The time to strengthen clinical, research, and manufacturing infrastructure to permit us to be ready to confront the next new virulent pathogen is now."

Journal • Infectious Disease

Creating a plasma coordination center to support COVID-19 outpatient trials across a national network of hospital blood banks. (PubMed, J Clin Transl Sci) - "A core investigational team adapted a cloud-based platform to randomize patient assignments and track inventory distribution of control plasma and high-titer COVID-19 convalescent plasma of different blood groups from 29 donor collection centers directly to blood banks serving 26 transfusion sites. Distributing more than 3,100 plasma units to blood banks charged with managing investigational inventory across the U.S. in a decentralized manner posed operational and regulatory challenges while providing opportunities for the plasma coordination center to contribute to research of global importance. This program can serve as a template in subsequent public health emergencies."

Journal • Infectious Disease • Novel Coronavirus Disease

Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma. (PubMed, Proc Natl Acad Sci U S A) - "CCP deployment was a successful strategy for ameliorating the impact of the COVID-19 pandemic in the USA. This experience has important implications for convalescent plasma use in future infectious disease emergencies."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Descriptions of Scientific Evidence and Uncertainty of Unproven COVID-19 Therapies in US News: Content Analysis Study. (PubMed, JMIR Infodemiology) - "These results highlight that while scientific evidence is discussed relatively frequently in news reports, scientific uncertainty is infrequently reported and rarely found in prominent headlines and lead paragraphs."

Journal • Infectious Disease • Novel Coronavirus Disease

The Importance of Geographic Proximity of Convalescent Plasma Donors. (PubMed, Curr Top Microbiol Immunol) - "Our recommendations include prioritizing virus genotyping for vulnerable patients, establishing a robust testing infrastructure, and collecting additional donor data to enhance plasma selection. This chapter underscores the importance of comprehensive data collection and sharing to navigate the evolving landscape of newly emerging infectious diseases."

Journal • Infectious Disease • Novel Coronavirus Disease

Convalescent plasma and predictors of mortality among hospitalized COVID-19 patients: a systematic review and meta-analysis. (PubMed, Clin Microbiol Infect) - "In-hospital transfusion of CCP within 7 days from symptom onset conferred a mortality benefit."

Clinical • Journal • Retrospective data • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Convalescent Plasma and the US Expanded Access Program: A Personal Narrative. (PubMed, Curr Top Microbiol Immunol) - "Writing just 4 years after the initiation of the EAP, this intense professional effort, comprising many moving parts, remains hard to completely understand or fully explain in this brief narrative. As Nelson Mandela said of the perception of time during his decades in prison, "the days seemed like years, and the years seemed like days.""

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Passive immunotherapies for the next influenza pandemic. (PubMed, Rev Med Virol) - "We review here the phylogeny of former influenza pandemics, and discuss candidate lineages. After briefly reviewing the other existing antiviral options, we discuss in detail the evidences supporting the efficacy of passive immunotherapies against influenzavirus, with a focus on convalescent plasma."

Journal • Review • Infectious Disease • Influenza • Respiratory Diseases

Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19. (PubMed, mBio) - "We found that the administration of vaccine-boosted convalescent plasma was associated with a significantly decreased incidence of hospitalization among immunocompromised COVID-19 outpatients. Our data add to the contemporary data providing evidence to support the clinical utility of high-titer convalescent plasma as antibody replacement therapy in immunocompromised patients."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Efficacy of Convalescent Plasma Combined with Other Pharmaceutical Agents for Treatment of COVID-19 in Hospitalized Patients: A Systematic Review and Meta-Analysis. (PubMed, Diseases) - "Plasma collected from people recovered from COVID-19 (COVID-19 convalescent plasma, CCP) was the first antibody-based therapy employed to fight the pandemic. The current evidence from the literature suggests a potential beneficial effect on mortality of combined CCP plus remdesivir compared to CCP alone in hospitalized COVID-19 patients. No significant clinical interaction was found between CCP and steroids."

Journal • Retrospective data • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing. (PubMed, Clin Infect Dis) - "The high seroprevalence of antibodies against SARS-CoV-2 worldwide limits the utility of detecting anti-SARS CoV-2 antibody. The certainty of available evidence supporting the use of serology for diagnosis was graded as very low to low. Future studies should use serologic assays calibrated to a common reference standard."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial. (PubMed, JCI Insight) - P2 | "High antibody level plasma units, given early, should be reserved for therapeutic use. Trial registration: NCT04373460 FUNDING Defense Health Agency and others."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Convalescent plasma: An unexpected new therapeutic option for critically ill COVID-19 patients coming from the past. (PubMed, J Clin Anesth) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease

Convalescent Plasma for Covid-19-Induced ARDS. (PubMed, N Engl J Med) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease

Safety of COVID-19 convalescent plasma: A definitive systematic review and meta-analysis of randomized controlled trials. (PubMed, Transfusion) - No abstract available

Journal • Retrospective data • Review • Cardiovascular • Infectious Disease • Novel Coronavirus Disease

COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients. (PubMed, Sci Rep) - "COVID-19 directed therapy included anti-spike monoclonal antibodies (n = 30, 20.8%), and, among those hospitalized within 14 days (n = 50), remdesivir (n = 45, 90.0%), glucocorticoids (n = 36, 72.0%) and convalescent plasma (n = 24, 48.0%). Administration of convalescent plasma within 14 days of the COVID-19 diagnosis was not significantly associated with any study outcome. Further study of COVID-19 in CD20-depleted individuals is needed focusing on the early administration of new and potentially combination antiviral agents, associated or not with vaccine-boosted convalescent plasma."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial. (PubMed, Microbiol Spectr) - "This decrease in IL-6 levels after early CCP treatment suggests a possible role of inflammation in COVID-19 progression. The evidence of IL-6 involvement brings insight into the possible mechanisms involved in CCP treatment mitigating SARS-CoV-2 severity."

Journal • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • IL6

Recommendations on the use of COVID-19 Convalescent Plasma to Treat Immunocompromised Patients. (PubMed, Semin Thromb Hemost) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease

The value of observational registry studies for the next infectious disease emergency. (PubMed, mBio) - "During the SARS-CoV-2 pandemic, several countries used registries to track the use of COVID-19 convalescent plasma (CCP). Those registries provided evidence that CCP was effective when used early and with high titer."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis. (PubMed, Mayo Clin Proc Innov Qual Outcomes) - "Second, earlier treatment with COVID-19 convalescent plasma was associated with a decrease in mortality compared with the later treatment cohort (OR, 0.63; 95% CI, 0.48 to 0.82). During COVID-19 convalescent plasma use was associated with a 13% reduced risk of mortality, implying a mortality benefit for hospitalized patients with COVID-19, particularly those treated with convalescent plasma containing high antibody levels treated earlier in the disease course."

Clinical • Journal • Retrospective data • Review • Infectious Disease • Novel Coronavirus Disease

Sex Differences In Troponin In Covid-19 Patients (HFSA 2023) - "Previous reports indicate that more men develop COVID-19 and have more severe disease, which may indicate a differential response to SARS-CoV-2.Hypothesis: We hypothesized that patients with elevated troponin (TnT) levels would have increased mortality due to COVID-19 and present with more cardiovascular serious adverse events and that This predictive biomarker would have sex-specific findings. The United States (US) convalescent plasma expanded access program (EAP) provided access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2... We and others have found that sex differences exist in the prevalence and severity of COVID-19 patients. Specifically understanding the cardiovascular risks associated with COVID and how troponin labs relate to the risk of mortality and adverse events due to COVID is important for clinical decision making. Understanding sex differences in COVID-19 may lead to a more individualized approach..."

Clinical • Cardiovascular • Immunology • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases

Early antibody treatment, inflammation, and risk of post-COVID conditions. (PubMed, mBio) - "In addition, among individuals treated early, within 5 days of symptom onset, with COVID-19 convalescent plasma, there was a trend for decreased odds of PCC after adjusting for other demographic and clinical characteristics. Future treatment studies should be considered to evaluate the effect of early treatment and anti-IL-6 therapies on PCC development."

Clinical • Journal • Diabetes • Fatigue • Genetic Disorders • Infectious Disease • Inflammation • Metabolic Disorders • Novel Coronavirus Disease • Obesity • Respiratory Diseases

Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study. (PubMed, Lancet Microbe) - "Initially and during recovery from symptomatic COVID-19, fully vaccinated participants had lower concentrations of inflammatory markers than unvaccinated participants suggesting vaccination is associated with short-term and long-term reduction in inflammation, which could in part explain the reduced disease severity and mortality in vaccinated individuals."

Journal • Cardiovascular • Diabetes • Hypertension • Infectious Disease • Inflammation • Metabolic Disorders • Novel Coronavirus Disease • Oncology • Respiratory Diseases • CCL2 • CXCL8 • IFNL1 • IL15 • IL7

The emergency use authorization for COVID-19 convalescent plasma reduced mortality. (PubMed, Health Sci Rep) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease